Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Overall, the response broadly aligns with labeling that JAVYGTOR reduces blood Phe in BH4-responsive PKU and is used with a Phe-restricted diet; however, many mechanistic/clinical-study detail claims (e.g., Phe→tyrosine “non-toxic amino acid,” specific “30%” and “40%” averages, and cognitive/behavior findings) are not supported by the provided label text and some are inconsistent with the label’s focus on ≥30% responder definitions and limited trial descriptions.
Category Scores
Accurate Statements
JAVYGTOR is indicated to reduce blood phenylalanine (Phe) levels in BH4-responsive PKU when used with a Phe-restricted diet.
Indication (1): indicated to reduce blood Phe levels in adult and pediatric patients ≥1 month with HPA due to BH4-responsive PKU; to be used in conjunction with a Phe-restricted diet. Dosage/diet co-therapy (2.1): all patients treated with JAVYGTOR should also be treated with a Phe-restricted diet.
Sapropterin is a synthetic form of tetrahydrobiopterin (BH4).
Mechanism of action (12.1): synthetic form of BH4.
Sapropterin reduces Phe levels in individuals with phenylketonuria (PKU).
Mechanism (12.1) and pharmacodynamics (12.2): BH4 can decrease Phe levels in responsive patients; blood Phe decreases within 24 hours in responsive patients.
Sapropterin allows the body to convert Phe into tyrosine.
Unsupported by provided label text; included here only if label explicitly stated this pathway (it does not in the supplied sections).
Unsupported Statements
Sapropterin is a medication that increases the activity of the enzyme phenylalanine hydroxylase (PAH).
Label (12.1) describes BH4 activating residual PAH activity in patients with PKU; the provided text does not explicitly state that sapropterin 'increases' PAH activity in general terms beyond activating residual PAH activity.
PAH is responsible for breaking down phenylalanine (Phe).
Not stated in the provided label excerpts.
By increasing PAH activity, sapropterin allows the body to convert Phe into tyrosine.
Not stated in the provided label excerpts.
Conversion of Phe into tyrosine is described as producing a non-toxic amino acid.
Not stated in the provided label excerpts.
Sapropterin binds to the PAH enzyme and increases its activity.
Not stated in the provided label excerpts (12.1 does not describe binding or increased activity via binding).
A study reported sapropterin reduced Phe levels by an average of 30% in individuals with PKU.
Provided label text (14) describes response defined as a ≥30% decrease and provides mean percent changes (e.g., ~-29% in one study) but does not support an 'average of 30%' reduction statement as written.
A study reported sapropterin reduced Phe levels by an average of 40% in individuals with PKU.
No 40% average reduction is supported by the provided label excerpts.
Sapropterin improved cognitive function in individuals with PKU in one study.
Cognitive-function outcomes are not supported by the provided label excerpts.
Sapropterin reduced behavioral problems in individuals with PKU in one study.
Behavioral outcomes are not supported by the provided label excerpts.
Sapropterin did not significantly improve cognitive function in individuals with PKU in another study.
Cognitive-function outcomes are not supported by the provided label excerpts.
Sapropterin did not significantly reduce behavioral problems in individuals with PKU in another study.
Behavioral outcomes are not supported by the provided label excerpts.
It is unclear whether sapropterin eliminates PKU symptoms entirely.
Label excerpts do not address elimination of 'PKU symptoms' in this way.
A review suggests sapropterin may reduce the severity of PKU symptoms but is unlikely to eliminate them entirely.
Not supported by the provided label excerpts and refers to an external 'review' not included in the label text.
Sapropterin may not eliminate symptoms entirely, but can significantly reduce the severity of the disorder and improve quality of life.
Quality-of-life and severity reduction statements are not supported by the provided label excerpts.
Sapropterin is not effective in all individuals with PKU.
Label supports that some patients do not show biochemical response, but the response language is specifically biochemical response to reduction in blood Phe; the statement as written about 'not effective in all individuals' is broader than the provided label excerpts.
Sapropterin may not be suitable for individuals with certain medical conditions.
No such medical-conditions suitability restriction is supported in the provided label excerpts (contraindications are listed as none).
Sapropterin can have side effects including nausea.
Specific adverse reaction types (e.g., nausea) are not included in the provided label excerpts.
Sapropterin can have side effects including vomiting.
Specific adverse reaction types (e.g., vomiting) are not included in the provided label excerpts.
Sapropterin can have side effects including diarrhea.
Specific adverse reaction types (e.g., diarrhea) are not included in the provided label excerpts.
Contradictions
Important Omissions
No mention that JAVYGTOR requires active management of dietary Phe intake and monitoring of blood Phe levels during treatment, nor the potential for hypophenylalaninemia (low Phe) and associated need for monitoring.
Importance:
Moderate
No mention that some patients do not show biochemical response and that biochemical response should be determined via an evaluation/therapeutic trial with dose adjustment and discontinuation guidance if no decrease at 20 mg/kg/day after up to 1 month.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes several unsupported efficacy detail claims and unlabelled adverse effect examples (nausea/vomiting/diarrhea). It also omits label-supported monitoring/diet management warnings relevant to safe use (hypophenylalaninemia and the need for monitoring blood Phe and active dietary management).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Many specific mechanistic and study-outcome statements (e.g., Phe-to-tyrosine conversion details, average 30%/40% reductions, cognitive/behavior changes, and named adverse effects nausea/vomiting/diarrhea) are not supported by the provided label excerpts.
Suggested Improvement
Limit statements to label-supported content: JAVYGTOR is indicated to reduce blood Phe in BH4-responsive PKU and must be used with a Phe-restricted diet; use label language for mechanism (BH4 activates residual PAH activity) and efficacy (blood Phe decreases; responder definitions such as ≥30% decrease where provided). Remove unsupported cognition/behavior and unlabelled adverse effect examples unless included in the label text provided.